Unravelling the complexity of <i>EGFR</i>-mutated lung adenocarcinoma: a unique case report with histological transformations and co-alteration acquisition.

ABSTRACT:

Background

Osimertinib, a third-generation tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR), specifically inhibits both EGFR tyrosine kinase inhibitor-sensitive mutations and T790M resistance mutations. Despite initial positive responses to EGFR tyrosine kinase inhibitors, nearly all patients eventually experience disease progression. Mechanisms of resistance are classically divided into EGFR-dependent and EGFR-independent mechanisms, such as the activation of alternative pathways and histological changes. We report a case of histological transformation into large cell carcinoma associated with the subsequent acquisition of an anaplastic lymphoma kinase (ALK) rearrangement after osimertinib exposure.

Case description

A 67-year-old female with no

SUBMITTER: Boutahir A 

PROVIDER: S-EPMC11921265 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature